3 minute read
Oct. 29, 2022
Upacicalcet: a CaSR Agonist Being Developed for SHPT
upacicalcet
IV CaSR agonist Ph. III candidate in secondary hyperparathyroidism identified from "kokumi-flavor" studies of peptides Mol. Pharmacol., Oct 1, 2022 Sanwa Kagaku Kenkyusho, Mie, JP
Loading...
